MariMed Inc. Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative) $ / shares in Units, $ in Millions	Feb. 29, 2020 USD ($) $ / shares shares
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price of Common Stock [Member]
Entity Listings [Line Items]
Preferred stock, conversion price	$ 4.00
Number of trading days, description	twenty consecutive trading days
Series B preferred stock conversion price, description	If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $
Series B Holders [Member]
Entity Listings [Line Items]
Share issued price	$ 3.00
Preferred stock, conversion price	$ 1.00
Exchange Agreement [Member] \| Two Institutional Shareholders [Member] \| Two Promissory Notes [Member]
Entity Listings [Line Items]
Debt Instrument, Face Amount \| $	$ 4.4
Exchange Agreement [Member] \| Two Institutional Shareholders [Member] \| Series B Convertible Preferred Stock [Member]
Entity Listings [Line Items]
Stock Issued During Period Shares Exchanged \| shares	4,908,333
Treasury stock per share value	$ 3.00